Company intelligence / Profile preview

Hepatera

Moscow, Russia

Ownership: Private
Development stage: Other

Overview

Myrcludex B has shown promising efficacy in Phase 2a trials. Phase 2b clinical trials for Myrcludex B in combination with tenofovir for HBV/HDV co-infected patients have completed patient recruitment with 120 patients across 15 clinical centers in Russia and Germany. The drug has received PRIME eligibility from the European Medicines Agency (EMA), recognizing its potential to address an unmet medical need.

Therapeutic areas: Infectious Diseases
Modalities: Peptide-based entry inhibitor
Industry: Biotech

Partnerships

MYR GmbH (Germany)University Hospital Heidelberg

Beyond the preview

Go deeper on Hepatera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatera.